<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: no products approved", fill: "#800020"},
{source: "3: no products approved", target: "3: conducting research", fill: "#800020"},
{source: "3: conducting research", target: "3: development on", fill: "#800020"},
{source: "3: development on", target: "3: product candidates", fill: "#800020"},
{source: "3: no products approved", target: "4: commercialization", fill: "#a2add0"},
{source: "4: commercialization", target: "9: development", fill: "#9f8170"},
{source: "9: development", target: "9: commercialization", fill: "#9f8170"},
{source: "9: development", target: "10: As of December ", fill: "#004040"},
{source: "10: As of December ", target: "10: accumulated deficit", fill: "#004040"},
{source: "10: accumulated deficit", target: "10: incur significant increasing", fill: "#004040"},
{source: "10: incur significant increasing", target: "10: losses over", fill: "#004040"},
{source: "10: losses over", target: "10: several years", fill: "#004040"},
{source: "10: As of December ", target: "19: regulators", fill: "#d1e231"},
{source: "19: regulators", target: "19: extensively", fill: "#d1e231"},
{source: "19: extensively", target: "19: rigorously", fill: "#d1e231"},
{source: "19: rigorously", target: "19: manufacture", fill: "#d1e231"},
{source: "19: manufacture", target: "19: distribution", fill: "#d1e231"},
{source: "19: distribution", target: "19: advertising", fill: "#d1e231"},
{source: "19: regulators", target: "20: approval process", fill: "#9ab973"},
{source: "20: approval process", target: "20: preclinical studies", fill: "#9ab973"},
{source: "20: preclinical studies", target: "20: pharmaceutical", fill: "#9ab973"},
{source: "20: pharmaceutical", target: "20: effectiveness", fill: "#9ab973"},
{source: "20: effectiveness", target: "20: each product", fill: "#9ab973"},
{source: "20: each product", target: "20: confirmation by", fill: "#9ab973"},
{source: "20: confirmation by", target: "20: regulators", fill: "#9ab973"},
{source: "20: regulators", target: "20: manufacturer", fill: "#9ab973"},
{source: "20: manufacturer", target: "20: laboratory", fill: "#9ab973"},
{source: "20: laboratory", target: "20: manufacturing", fill: "#9ab973"},
{source: "20: approval process", target: "38: NDA for Surfaxin ", fill: "#cf3476"},
{source: "38: NDA for Surfaxin ", target: "38: timely manner", fill: "#cf3476"},
{source: "38: timely manner", target: "38: which would", fill: "#cf3476"},
{source: "38: which would", target: "38: adversely impact", fill: "#cf3476"},
{source: "38: adversely impact", target: "38: commercialize", fill: "#cf3476"},
{source: "38: NDA for Surfaxin ", target: "85: additional financing could", fill: "#ff5a36"},
{source: "85: additional financing could", target: "85: equity dilution", fill: "#ff5a36"},
{source: "85: additional financing could", target: "93: entered into arrangements", fill: "#5218fa"},
{source: "93: entered into arrangements", target: "93: arrangement", fill: "#5218fa"},
{source: "93: arrangement", target: "93: additional financing", fill: "#5218fa"},
{source: "93: additional financing", target: "93: Kingsbridge ", fill: "#5218fa"},
{source: "93: Kingsbridge ", target: "93: facility with", fill: "#5218fa"},
{source: "93: facility with", target: "93: PharmaBio ", fill: "#5218fa"},
{source: "93: PharmaBio ", target: "93: additional financing could", fill: "#5218fa"},
{source: "93: additional financing could", target: "93: unattractive terms", fill: "#5218fa"},
{source: "93: unattractive terms", target: "93: significant", fill: "#5218fa"},
{source: "93: significant", target: "93: stockholders interests", fill: "#5218fa"},
{source: "93: stockholders interests", target: "93: prices may", fill: "#5218fa"},
{source: "93: entered into arrangements", target: "96: dilutive impact on", fill: "#fc6c85"},
{source: "96: dilutive impact on", target: "96: stockholders", fill: "#fc6c85"},
{source: "96: dilutive impact on", target: "97: Furthermore ", fill: "#fc0"},
{source: "97: Furthermore ", target: "97: market price", fill: "#fc0"},
{source: "97: market price", target: "97: common stock declines as", fill: "#fc0"},
{source: "97: common stock declines as", target: "97: dilutive aspects", fill: "#fc0"},
{source: "97: dilutive aspects", target: "97: such potential financings", fill: "#fc0"},
{source: "97: such potential financings", target: "97: could cease", fill: "#fc0"},
{source: "97: could cease", target: "97: financial requirements", fill: "#fc0"},
{source: "97: financial requirements", target: "97: securities on", fill: "#fc0"},
{source: "97: Furthermore ", target: "100: common stock", fill: "#1c352d"},
{source: "100: common stock", target: "100: issuance under", fill: "#1c352d"},
{source: "100: issuance under", target: "100: arrangement with", fill: "#1c352d"},
{source: "100: arrangement with", target: "100: Kingsbridge ", fill: "#1c352d"},
{source: "100: Kingsbridge ", target: "100: issuable under", fill: "#1c352d"},
{source: "100: common stock", target: "START_HERE", fill: "#1c352d"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cellulosic_ethanol">Cellulosic ethanol</a></td>
      <td>Cellulosic ethanol is ethanol (ethyl alcohol) produced from cellulose (the stringy fiber of a plant) rather than from the plant's seeds or fruit. It can be produced from grasses, wood, algae, or other plants.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bioprospecting">Bioprospecting</a></td>
      <td>Bioprospecting (also known as biodiversity prospecting) is the exploration of natural sources for small molecules, macromolecules and biochemical and genetic information that could be developed into commercially valuable products for the agricultural, aquaculture, bioremediation, cosmetics, nanotechnology, or pharmaceutical industries. In the pharmaceutical industry, for example,  almost one third of all small-molecule drugs approved by the U.S. Food and Drug Administration (FDA) between 1981 and 2014 were either natural products or compounds derived from natural products.Terrestrial plants, fungi and actinobacteria have been the focus of many past bioprospecting programs, but interest is growing in less explored ecosystems (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management_development">Management development</a></td>
      <td>Management development is the process by which managers learn and improve their management skills.\n\n\n== Background ==\nIn organisational development, management effectiveness is recognized as a determinant of organisational success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Equity_(finance)">Equity (finance)</a></td>
      <td>In finance, equity is ownership of assets that may have debts or other liabilities attached to them. Equity is measured for accounting purposes by subtracting liabilities from the value of the assets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_manufacturing">Pharmaceutical manufacturing</a></td>
      <td>Pharmaceutical manufacturing is the process of industrial-scale synthesis of pharmaceutical drugs as part of the pharmaceutical industry.  The process of drug manufacturing can be broken down into a series of unit operations, such as milling, granulation, coating, tablet pressing, and others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Kendrick_Lamar">Kendrick Lamar</a></td>
      <td>Kendrick Lamar Duckworth (born June 17, 1987) is an American rapper, songwriter, and record producer. He is often cited as one of the most influential rappers of his generation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Windows_Notepad">Windows Notepad</a></td>
      <td>Windows Notepad is a simple text editor for Windows; it creates and edits plain text documents. First released in 1983 to commercialize the computer mouse in MS-DOS, Notepad has been part of every version of Windows ever since.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Friedman_doctrine">Friedman doctrine</a></td>
      <td>The Friedman doctrine, also called shareholder theory or stockholder theory, is a normative theory of business ethics advanced by economist Milton Friedman which holds that the social responsibility of business is to increase its profits. This shareholder primacy approach views shareholders as the economic engine of the organization and the only group to which the firm is socially responsible.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Derivative_suit">Derivative suit</a></td>
      <td>A shareholder derivative suit is a lawsuit brought by a shareholder on behalf of a corporation against a third party. Often, the third party is an insider of the corporation, such as an executive officer or director.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Shareholder">Shareholder</a></td>
      <td>A shareholder (in the United States often referred to as stockholder) of a corporation is an individual or legal entity (such as another corporation, a body politic, a trust or partnership) that is registered by the corporation as the legal owner of shares of the share capital of a public or private corporation. Shareholders may be referred to as members of a corporation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stockholder_of_record">Stockholder of record</a></td>
      <td>Stockholder of record is the name of an individual or entity shareholder that an issuer carries in its shareholder register as the registered holder (not necessarily the beneficial owner) of the issuer's securities. Dividends and other distributions are paid only to shareholders of record.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Annual_general_meeting">Annual general meeting</a></td>
      <td>An annual general meeting (AGM, also known as the annual meeting) is a meeting of the general membership of an organization.\nThese organizations include membership associations and companies with shareholders.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Public_company">Public company</a></td>
      <td>A public company, publicly traded company, publicly held company, publicly listed company, or public limited company is a company whose ownership is organized via shares of stock which are intended to be freely traded on a stock exchange or in over-the-counter markets. A public (publicly traded) company can be listed on a stock exchange (listed company), which facilitates the trade of shares, or not (unlisted public company).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Jessica_Stockholder">Jessica Stockholder</a></td>
      <td>Jessica Stockholder (born 1959) is a Canadian-American artist known for site-specific installation works and sculptures that are often described as "paintings in space." She came to prominence in the early 1990s with monumental works that challenged boundaries between artwork and display environment as well as between pictorial and physical experience. Her art often presents a "barrage" of bold colors, textures and everyday objects, incorporating floors, walls and ceilings and sometimes spilling out of exhibition sites.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Treasury_stock">Treasury stock</a></td>
      <td>A treasury stock or reacquired stock is stock which is bought back by the issuing company, reducing the amount of outstanding stock on the open market ("open market" including insiders' holdings). \nStock repurchases are used as a tax efficient method to put cash into shareholders' hands, rather than paying dividends, in jurisdictions that treat capital gains more favorably.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>DISCOVERY LABORATORIES INC /DE/      ITEM 1A     RISK FACTORS       The  following  risks,  among  others, could cause our actual results,     performance, achievements or industry results to <font color="blue">differ materially from</font>     those expressed in our forward-looking statements contained herein and     <font color="blue">presented elsewhere by management from</font> time to time</td>
    </tr>
    <tr>
      <td>We may not <font color="blue">successfully</font> develop and market our products, and even if we do,     we may not <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>We  currently have <font color="blue">no products approved</font> for marketing and sale and are     <font color="blue">conducting research</font> and <font color="blue"><font color="blue">development</font> on</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>As a result,     we have not begun to market or generate <font color="blue">revenues from</font> the <font color="blue">commercialization</font>     of any of our products</td>
    </tr>
    <tr>
      <td>Our long-term viability will be impaired if we are     unable  to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for, or <font color="blue">successfully</font> market, our     <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>To date, we have only generated <font color="blue">revenues from</font> <font color="blue">investment</font>s, research grants     and <font color="blue">collaborative research</font> and <font color="blue"><font color="blue">development</font> <font color="blue"><font color="blue">agreement</font>s</font></font></td>
    </tr>
    <tr>
      <td>We will need to     engage in <font color="blue">significant</font>, time-consuming and costly research, <font color="blue">development</font>,     pre-<font color="blue">clinical studies</font>, <font color="blue">clinical testing</font> and <font color="blue"><font color="blue">regulatory</font> approval</font> for our     <font color="blue">products under <font color="blue">development</font> prior</font> to their <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>In addition,     pre-clinical  or  clinical  <font color="blue">studies may show</font> that our products are not     <font color="blue">effective</font> or safe for one or more of their <font color="blue">intended uses</font></td>
    </tr>
    <tr>
      <td>We may fail in the     <font color="blue">development</font> and <font color="blue">commercialization</font> of our products</td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005,     we have an <font color="blue">accumulated deficit</font> of approximately dlra202dtta0 million and we expect     to continue to <font color="blue">incur <font color="blue">significant</font> increasing</font> operating <font color="blue">losses over</font> the next     <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>If we succeed in the <font color="blue">development</font> of our products, we still     may  not  <font color="blue">generate sufficient</font> or <font color="blue">sustainable revenues</font> or we may not be     profitable</td>
    </tr>
    <tr>
      <td>Our   <font color="blue">technology</font>   platform   is   based  solely  on  our  <font color="blue">proprietary</font>     precision-engineered surfactant <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our precision-engineered surfactant <font color="blue">technology</font> platform is <font color="blue">based on</font> the     <font color="blue">scientific rationale</font> of using SRT to treat life-threatening <font color="blue">respiratory</font>     disorders and as the foundation for the <font color="blue">development</font> of novel <font color="blue">respiratory</font>     therapies  and products</td>
    </tr>
    <tr>
      <td>Our business is <font color="blue">dependent upon</font> the successful     <font color="blue">development</font> and approval of our <font color="blue">product <font color="blue">candidates</font></font> <font color="blue">based on</font> this <font color="blue">technology</font>     platform</td>
    </tr>
    <tr>
      <td>Any material <font color="blue">problems with</font> our <font color="blue">technology</font> platform could have a     material adverse effect on our business</td>
    </tr>
    <tr>
      <td>The  <font color="blue">regulatory</font>  approval  process  for  our products is expensive and     time-consuming, and the outcome is uncertain</td>
    </tr>
    <tr>
      <td>We may not obtain required     <font color="blue"><font color="blue">regulatory</font> approval</font>s for the <font color="blue">commercialization</font> of our products</td>
    </tr>
    <tr>
      <td>In order to sell Surfaxin or any of our other products under <font color="blue">development</font>, we     must receive <font color="blue"><font color="blue">regulatory</font> approval</font>s for <font color="blue">each product</font></td>
    </tr>
    <tr>
      <td>The FDA and foreign     <font color="blue">regulators</font> <font color="blue">extensively</font> and <font color="blue">rigorously</font> regulate the testing, <font color="blue">manufacture</font>,     <font color="blue">distribution</font>, <font color="blue">advertising</font>, pricing and marketing of <font color="blue"><font color="blue">drug product</font>s</font> like our     products</td>
    </tr>
    <tr>
      <td>This <font color="blue">approval process</font> includes <font color="blue">pre<font color="blue">clinical studies</font></font> and clinical     trials  of  each  <font color="blue">pharmaceutical</font>  compound to establish the safety and     <font color="blue">effective</font>ness of <font color="blue">each product</font> and the <font color="blue">confirmation by</font> the FDA and foreign     <font color="blue">regulators</font> that the <font color="blue">manufacture</font>r of the product maintains good <font color="blue">laboratory</font>     and  <font color="blue">manufacturing</font> practices during testing and <font color="blue">manufacturing</font></td>
    </tr>
    <tr>
      <td>Even if     favorable <font color="blue">testing data</font> is <font color="blue">generated by <font color="blue">clinical trials</font></font> of <font color="blue"><font color="blue">drug product</font>s</font>, the     FDA  or  EMEA  may  not  accept  or  approve  an <font color="blue">NDA or MAA </font>filed by a     <font color="blue">pharmaceutical</font> or bio<font color="blue">technology</font> company for <font color="blue">such <font color="blue">drug product</font></font></td>
    </tr>
    <tr>
      <td>To market our     <font color="blue">products outside</font> the United States, we also need to <font color="blue"><font color="blue">comply with</font> foreign</font>     <font color="blue">regulatory</font>  <font color="blue"><font color="blue">requirements</font> governing human <font color="blue">clinical trials</font></font> and marketing     approval for <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td>We have filed an NDA with the <font color="blue">FDA for Surfaxin </font>for the prevention of RDS in     <font color="blue">premature infants</font></td>
    </tr>
    <tr>
      <td>As part of the review of the Surfaxin NDA, the FDA, in     January 2005, issued a Form 483 to our then contract <font color="blue">manufacture</font>r, Laureate     Pharma, Inc</td>
    </tr>
    <tr>
      <td><font color="blue">citing inspectional <font color="blue">observations</font></font> related to <font color="blue">basic quality</font>     controls, process assurances and <font color="blue">documentation <font color="blue">requirements</font></font> that support the     commercial  production  process  <font color="blue">necessary</font> to <font color="blue"><font color="blue">comply with</font> current</font> good     <font color="blue">manufacturing</font> practices (cGMPs)</td>
    </tr>
    <tr>
      <td>The FDA issued an <font color="blue">Approvable Letter </font>to us     <font color="blue">in February </font>2005 regarding our NDA To address the Form 483 inspectional     <font color="blue">observations</font>, we and Laureate <font color="blue">implemented improved quality systems</font> and     <font color="blue">documentation controls</font> believed to support the FDA’s <font color="blue">regulatory</font> <font color="blue">requirements</font>     for  the  approval  of Surfaxin</td>
    </tr>
    <tr>
      <td>In October 2005, the FDA accepted our     responses  to  the  Approvable  Letter  as a complete <font color="blue">response thereby</font>     <font color="blue">establishing</font> April 2006 as its target to complete its review of our NDA     Assuming that the <font color="blue">corrective actions</font> made to the Surfaxin <font color="blue">manufacturing</font>     operation in Totowa, NJ are adequate, we anticipate that our NDA will be     approved in April 2006 and that the US <font color="blue">commercial launch</font> of Surfaxin will     occur late in the <font color="blue">second quarter</font> of 2006</td>
    </tr>
    <tr>
      <td>The FDA, however, might still     delay its approval of our NDA or reject our NDA, <font color="blue">which would</font> have a material     adverse effect on our business</td>
    </tr>
    <tr>
      <td><font color="blue">In February </font>2006, we     received the Day 180 <font color="blue">List of Outstanding Issues </font>from the <font color="blue">Committee </font>for     Medicinal Products for Human Use (CHMP) in relation to our MAA We plan to     submit a <font color="blue">written response</font> to all of the CHMP’s <font color="blue">outstanding issues</font> in early     April 2006 with a possible <font color="blue">Oral Explanation </font>before the CHMP in late <font color="blue">June     </font>2006</td>
    </tr>
    <tr>
      <td><font color="blue">According </font>to standard CHMP procedures, the <font color="blue">Committee </font>is expected to     make a <font color="blue">recommendation on whether</font> to grant a <font color="blue">Marketing Authorization </font>for     Surfaxin and issue a formal Opinion in late July 2006</td>
    </tr>
    <tr>
      <td>”       <font color="blue">If the FDA </font>and foreign <font color="blue">regulators</font> do not approve our products, we will not     be able to market our products</td>
    </tr>
    <tr>
      <td>The FDA and foreign <font color="blue">regulators</font> have not yet approved any of our products     under <font color="blue">development</font> for marketing in the <font color="blue">United States </font>or elsewhere</td>
    </tr>
    <tr>
      <td><font color="blue">The FDA     </font>or a <font color="blue">foreign regulator could withdraw</font> any approvals we obtain, if any</td>
    </tr>
    <tr>
      <td>Further, if there is a <font color="blue">later discovery</font> of <font color="blue">unknown problems</font> or if we fail to     <font color="blue">comply with</font> other applicable <font color="blue">regulatory</font> <font color="blue">requirements</font> at any stage in the     <font color="blue">regulatory</font> process, the FDA or a <font color="blue">foreign regulator <font color="blue">may restrict</font></font> or delay our     marketing of a product or force us to make <font color="blue">product recalls</font></td>
    </tr>
    <tr>
      <td>In addition, the     FDA <font color="blue">could impose</font> other sanctions such as fines, injunctions, civil penalties     or <font color="blue">criminal prosecutions</font></td>
    </tr>
    <tr>
      <td>Our pending <font color="blue">NDA for Surfaxin </font>for the prevention of RDS in <font color="blue">premature infants</font>     may not be <font color="blue">approved by</font> the FDA in a <font color="blue">timely manner</font> or at all, <font color="blue">which would</font>     <font color="blue"><font color="blue">adversely</font> impact</font> our ability to <font color="blue">commercialize</font> this product</td>
    </tr>
    <tr>
      <td>We submitted an NDA to the <font color="blue">FDA for Surfaxin </font>for the prevention of RDS in     <font color="blue">premature infants</font></td>
    </tr>
    <tr>
      <td><font color="blue">Under the Prescription Drug User Fee Act </font>of 1992, or     PDUFA,  <font color="blue">guidelines</font>, we expect that the FDA will complete its review or     otherwise respond to this NDA on or about April 6, 2006</td>
    </tr>
    <tr>
      <td>In <font color="blue"><font color="blue">connection</font> with</font>     its review, the FDA <font color="blue">may request <font color="blue">additional</font></font> information from us, including     <font color="blue">data from <font color="blue">additional</font> <font color="blue">clinical trials</font></font></td>
    </tr>
    <tr>
      <td>Ultimately, the FDA may not approve     <font color="blue">Surfaxin for RDS </font>in <font color="blue">premature infants</font></td>
    </tr>
    <tr>
      <td>Any failure to obtain FDA approval or     <font color="blue">further delay <font color="blue">associated with</font></font> the FDA’s <font color="blue">review process would <font color="blue">adversely</font></font>     impact our ability to <font color="blue">commercialize</font> our <font color="blue">lead product</font></td>
    </tr>
    <tr>
      <td>Even though some of our <font color="blue">drug <font color="blue">candidates</font></font> have qualified for <font color="blue">expedited review</font>,     the FDA may not <font color="blue">approve them at</font> all or any <font color="blue">sooner than</font> other <font color="blue">drug <font color="blue">candidates</font></font>     that do not qualify for <font color="blue">expedited review</font></td>
    </tr>
    <tr>
      <td>The  FDA  has <font color="blue">notified us</font> that two of our intended <font color="blue">indications</font> for our     precision-engineered SRT, BPD in <font color="blue">premature infants</font> and ARDS in adults, have     been granted <font color="blue">designation</font> as <font color="blue">Fast Track </font><font color="blue">products under provisions</font> of the Food     and Drug Administration Modernization Act of 1997</td>
    </tr>
    <tr>
      <td><font color="blue">Designation </font>as a Fast     Track product means that the FDA has determined that the drug is intended     for  the  treatment  of  a  serious  or life-threatening condition and     <font color="blue">demonstrates</font>  the  potential to <font color="blue">address unmet medical</font> needs for such a     condition, and that the FDA <font color="blue">will facilitate</font> and expedite the <font color="blue">development</font> and     review of the <font color="blue">application</font> for the approval of the product</td>
    </tr>
    <tr>
      <td>The FDA <font color="blue">generally</font>     <font color="blue">will review</font> an NDA for a <font color="blue">drug granted</font> <font color="blue">Fast Track </font><font color="blue">designation</font> within six     <font color="blue">months instead</font> of the <font color="blue">typical one</font> to <font color="blue">three years</font></td>
    </tr>
    <tr>
      <td><font color="blue">Fast Track </font><font color="blue">designation</font>     does not <font color="blue">accelerate <font color="blue">clinical trials</font> nor</font> does it mean that the <font color="blue">regulatory</font>     <font color="blue">requirements</font> are <font color="blue">less stringent</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">products may cease</font> to qualify for     <font color="blue">expedited review</font> and our other <font color="blue">drug <font color="blue">candidates</font></font> may fail to qualify for Fast     Track <font color="blue">designation</font> or <font color="blue">expedited review</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">ongoing <font color="blue">clinical trials</font> may</font> be delayed, or fail, which will harm our     business</td>
    </tr>
    <tr>
      <td>Clinical trials <font color="blue">generally</font> take two to <font color="blue">five years</font> or more to complete</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">first product</font> is not expected to be <font color="blue">commercially available</font> in the United     States until the <font color="blue">second quarter</font> of 2006 at the earliest, and our other     product  <font color="blue">candidates</font>  will  take  longer  to  <font color="blue">commercialize</font></td>
    </tr>
    <tr>
      <td>Like many     bio<font color="blue">technology</font> companies, we <font color="blue">may suffer <font color="blue">significant</font> setbacks</font> in advanced     <font color="blue">clinical trials</font>, even after obtaining promising results in <font color="blue">earlier trials</font> or     in  <font color="blue">preliminary</font>  findings for <font color="blue">such <font color="blue">clinical trials</font></font></td>
    </tr>
    <tr>
      <td>Data obtained from     <font color="blue">clinical trials</font> are susceptible to <font color="blue">varying interpretations which may delay</font>,     limit or prevent <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>In addition, we may be unable to     <font color="blue">enroll patients quickly enough</font> to meet our <font color="blue">expectations</font> for completing any     or all of these trials</td>
    </tr>
    <tr>
      <td>The timing and <font color="blue">completion</font> of current and planned     <font color="blue">clinical trials</font> of our <font color="blue">product <font color="blue">candidates</font></font> depend on, among other factors,     the  rate  <font color="blue">at which patients</font> are enrolled, which is a function of many     factors, including:       15       _________________________________________________________________       ·     the number of <font color="blue">clinical sites</font>;       ·     the size of the <font color="blue">patient population</font>;       ·     the proximity of patients to the <font color="blue">clinical sites</font>;       ·     the <font color="blue">eligibility</font> and <font color="blue"><font color="blue">enrollment</font> criteria</font> for the study;       ·     the existence of competing <font color="blue">clinical trials</font>;       ·     the existence of <font color="blue">alternative available products</font>; and       ·     <font color="blue">geographical</font> and <font color="blue">geopolitical considerations</font></td>
    </tr>
    <tr>
      <td>Delays in patient <font color="blue">enrollment</font> in <font color="blue">clinical trials</font> may occur, <font color="blue">which would</font>     likely result in increased costs, program delays or both</td>
    </tr>
    <tr>
      <td>Patients may also     <font color="blue">suffer adverse medical events</font> or side effects that are common to those     <font color="blue">administered with</font> the surfactant class of <font color="blue">drugs such as</font> a decrease in the     <font color="blue">oxygen level</font> of the <font color="blue">blood upon administration</font></td>
    </tr>
    <tr>
      <td>It is <font color="blue">also possible</font> that the FDA or foreign <font color="blue">regulators</font> could interrupt,     delay or halt any one or more of our <font color="blue">clinical trials</font> for any of our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If we or any regulator believe that <font color="blue">trial participants face</font>     unacceptable <font color="blue">health risks</font>, any one or more of our <font color="blue">trials could</font> be suspended     or terminated</td>
    </tr>
    <tr>
      <td>We also may not <font color="blue">reach <font color="blue">agreement</font> with</font> the FDA or a foreign     <font color="blue">regulator on</font> the design of any one or more of the <font color="blue">clinical studies</font> <font color="blue">necessary</font>     for approval</td>
    </tr>
    <tr>
      <td><font color="blue">Conditions </font><font color="blue">imposed by</font> the FDA and foreign <font color="blue">regulators</font> on our     clinical  trials  could  <font color="blue"><font color="blue">significant</font>ly</font>  increase the time required for     <font color="blue">completion</font> of <font color="blue">such <font color="blue">clinical trials</font></font> and the costs of conducting the clinical     trials</td>
    </tr>
    <tr>
      <td>In addition to our efforts to <font color="blue">commercialize</font> Surfaxin for the prevention of     RDS in <font color="blue">premature infants</font>, we are currently conducting two <font color="blue">clinical trials</font>: a     Phase  2  clinical  trial  to determine the safety and <font color="blue">tolerability</font> of     <font color="blue">administering</font> Surfaxin as a <font color="blue">therapeutic approach</font> for the prevention and     treatment  of BPD in <font color="blue">premature infants</font> <font color="blue">and a Phase </font>2 clinical trial to     address ARDS in adults</td>
    </tr>
    <tr>
      <td>We are preparing to <font color="blue">conduct multiple</font> Phase 2 pilot     <font color="blue">studies with</font> <font color="blue">Aerosurf </font>for the <font color="blue">potential treatment</font> of <font color="blue">premature infants</font> in     the NICU suffering from neonatal <font color="blue">respiratory</font> failure</td>
    </tr>
    <tr>
      <td>”       The <font color="blue">manufacture</font> of our products is a <font color="blue">highly exacting</font> and <font color="blue">complex process</font>,     and if we or one of our <font color="blue">materials suppliers</font> encounter problems <font color="blue">manufacturing</font>     our products, our business <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>The  FDA  and  foreign  <font color="blue">regulators</font>  require  <font color="blue">manufacture</font>rs to register     <font color="blue">manufacturing</font> <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>The FDA and foreign <font color="blue">regulators</font> also inspect these     <font color="blue">facilities</font> to confirm <font color="blue">compliance with</font> cGMP or similar <font color="blue">requirements</font> that the     FDA or foreign <font color="blue">regulators</font> establish</td>
    </tr>
    <tr>
      <td>We or our <font color="blue">materials suppliers</font> may face     <font color="blue">manufacturing</font> or quality control problems causing product production and     shipment delays or a situation where we or the <font color="blue">supplier may</font> not be able to     maintain <font color="blue">compliance with</font> the FDA’s cGMP <font color="blue">requirements</font>, or those of foreign     <font color="blue">regulators</font>,  <font color="blue">necessary</font>  to  continue <font color="blue">manufacturing</font> our drug substance</td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturing </font>or quality control problems have already and may again occur     at our Totowa <font color="blue">facility</font> or our <font color="blue">materials suppliers</font></td>
    </tr>
    <tr>
      <td>Any failure to comply     with cGMP <font color="blue">requirements</font> or other FDA or foreign <font color="blue">regulatory</font> <font color="blue">requirements</font> could     <font color="blue">adversely</font> affect our clinical research <font color="blue">activities</font> and our ability to market     and develop our products</td>
    </tr>
    <tr>
      <td><font color="blue">In <font color="blue">December </font></font>2005, we acquired Laureate’s clinical <font color="blue">manufacturing</font> <font color="blue">facility</font> in     Totowa, New Jersey</td>
    </tr>
    <tr>
      <td>The <font color="blue">facility</font> has <font color="blue">been qualified</font> to produce <font color="blue">appropriate</font>     <font color="blue">clinical grade</font> material of our <font color="blue">drug product</font> for use in our <font color="blue">ongoing clinical</font>     studies</td>
    </tr>
    <tr>
      <td>With this <font color="blue">acquisition</font>, we now maintain a complete <font color="blue">manufacturing</font>     <font color="blue">facility</font> and we will be <font color="blue">manufacturing</font> our products</td>
    </tr>
    <tr>
      <td>We currently own certain     specialized <font color="blue">manufacturing</font> equipment, employ certain <font color="blue">manufacturing</font> managerial     personnel, and we expect to invest in <font color="blue">additional</font> <font color="blue">manufacturing</font> equipment</td>
    </tr>
    <tr>
      <td>We     may be unable to produce Surfaxin and our <font color="blue">other SRT </font><font color="blue">drug <font color="blue">candidates</font></font> to     <font color="blue">appropriate</font> standards for use in <font color="blue">clinical studies</font></td>
    </tr>
    <tr>
      <td>If we do not <font color="blue">successfully</font>     develop our <font color="blue">manufacturing</font> <font color="blue">capabilities</font>, it will <font color="blue">adversely</font> affect the sales     of our products</td>
    </tr>
    <tr>
      <td>16       _________________________________________________________________       If the parties we depend on for supplying our drug substance <font color="blue">raw materials</font>     and  certain <font color="blue">manufacturing</font>-related services do not timely supply these     products  and services, it may delay or impair our ability to develop,     <font color="blue">manufacture</font> and market our products</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on suppliers</font> for our drug substance <font color="blue">raw materials</font> and <font color="blue">third parties</font>     for certain <font color="blue">manufacturing</font>-related services in order to produce material that     meets <font color="blue">appropriate</font> standards for commercial <font color="blue">distribution</font> and use in clinical     trials  of  our products</td>
    </tr>
    <tr>
      <td>To succeed, <font color="blue">clinical trials</font> require adequate     supplies of drug substance and <font color="blue">drug product</font>, which may be <font color="blue">difficult</font> or     uneconomical to procure or <font color="blue">manufacture</font></td>
    </tr>
    <tr>
      <td>We and our suppliers and vendors may     not be able to (i) produce our drug substance or <font color="blue">drug product</font> to <font color="blue">appropriate</font>     standards for use in <font color="blue">clinical studies</font>, (ii) perform under any <font color="blue">definitive</font>     <font color="blue">manufacturing</font>, supply or service <font color="blue"><font color="blue">agreement</font>s</font> with us or (iii) remain in     business  for a sufficient time to <font color="blue">successfully</font> produce and market our     product  <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If we do not maintain important <font color="blue">manufacturing</font> and     service  <font color="blue">relationships</font>,  we may fail to find a <font color="blue">replacement supplier</font> or     required vendor or develop our own <font color="blue">manufacturing</font> <font color="blue">capabilities</font> <font color="blue">which could</font>     delay or impair our ability to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for our products     and <font color="blue"><font color="blue">substantially</font> increase</font> our costs or <font color="blue">deplete profit margins</font>, if any</td>
    </tr>
    <tr>
      <td>If     we do find replacement <font color="blue">manufacture</font>rs and vendors, we may not be able to     <font color="blue">enter into</font> <font color="blue"><font color="blue">agreement</font>s</font> with them on terms and <font color="blue">conditions</font> favorable to us and,     <font color="blue">there could</font> be a substantial delay before a new <font color="blue">facility</font> could be qualified     and <font color="blue">registered with</font> the FDA and foreign <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>We will need <font color="blue"><font color="blue">additional</font> capital</font> and our ability to continue all of our     existing planned research and <font color="blue">development</font> <font color="blue">activities</font> is uncertain</td>
    </tr>
    <tr>
      <td>Any     <font color="blue"><font color="blue"><font color="blue">additional</font> financing</font> could</font> result in <font color="blue">equity dilution</font></td>
    </tr>
    <tr>
      <td>We will need substantial <font color="blue"><font color="blue">additional</font> funding</font> to conduct our presently planned     research and product <font color="blue">development</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Based on our current operating     plan,  we believe that our <font color="blue">currently available</font> working capital will be     adequate to satisfy our capital needs into the <font color="blue">second half</font> of 2006</td>
    </tr>
    <tr>
      <td>Our     future capital <font color="blue">requirements</font> will depend on a number of factors that are     uncertain, including the results of our research and <font color="blue">development</font> <font color="blue">activities</font>,     <font color="blue">clinical studies</font> and trials, <font color="blue">competitive</font> and <font color="blue"><font color="blue">technological</font> advances</font> and the     <font color="blue">regulatory</font> process, among others</td>
    </tr>
    <tr>
      <td>We <font color="blue">will likely</font> need to raise substantial     <font color="blue">additional</font> funds through collaborative ventures with potential corporate     partners and <font color="blue">through <font color="blue">additional</font> debt</font> or <font color="blue">equity <font color="blue">financings</font></font></td>
    </tr>
    <tr>
      <td>We     may in some <font color="blue">cases elect</font> to develop <font color="blue">products on</font> our own instead of entering     <font color="blue">into <font color="blue">collaboration</font> <font color="blue">arrangement</font>s</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">would increase</font> our cash <font color="blue">requirements</font>     for research and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We have not <font color="blue"><font color="blue">entered into</font> <font color="blue">arrangement</font>s</font> to obtain any <font color="blue"><font color="blue">additional</font> financing</font>,     except for <font color="blue">the CEFF </font>with Kingsbridge, our revolving credit <font color="blue">facility</font> with     <font color="blue">PharmaBio </font>and our capital equipment lease financing <font color="blue">arrangement</font> with GECC     Any <font color="blue"><font color="blue"><font color="blue">additional</font> financing</font> could</font> include <font color="blue">unattractive terms</font> or result in     <font color="blue">significant</font>  dilution  of <font color="blue">stockholders</font>’ interests and share <font color="blue">prices may</font>     decline</td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue"><font color="blue">enter into</font> collaborative ventures</font> or to receive     <font color="blue"><font color="blue">additional</font> funding</font>, we may have to delay, scale back or <font color="blue">discontinue certain</font>     of our research and <font color="blue">development</font> <font color="blue">operations</font>, and consider licensing the     <font color="blue">development</font> and <font color="blue">commercialization</font> of products that we consider valuable and     which we <font color="blue">otherwise would</font> have developed ourselves</td>
    </tr>
    <tr>
      <td>If we are unable to raise     required  capital,  we may be forced to limit many, if not all, of our     research  and  <font color="blue">development</font>  programs  and  related <font color="blue">operations</font>, curtail     <font color="blue">commercialization</font>  of  our  product  <font color="blue">candidates</font> and, ultimately, cease     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>See also Item 1A: “Risk Factors - Our Committed Equity Financing     Facility may have a <font color="blue">dilutive impact on</font> our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>”       Furthermore, if the <font color="blue">market price</font> of our <font color="blue"><font color="blue">common stock</font> declines as</font> a result of     the <font color="blue">dilutive aspects</font> of <font color="blue">such potential <font color="blue">financings</font></font>, we <font color="blue">could cease</font> to meet     the financial <font color="blue">requirements</font> to maintain the listing of our <font color="blue">securities on</font> The     NASDAQ <font color="blue">National Market</font></td>
    </tr>
    <tr>
      <td>See  Item 1A: “Risk Factors  The <font color="blue">market price</font> of our     stock may be <font color="blue">adversely</font> affected by market <font color="blue">volatility</font></td>
    </tr>
    <tr>
      <td>”       <font color="blue">Our Committed Equity Financing Facility </font>may have a <font color="blue">dilutive impact on</font> our     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>There  are 10cmam962cmam651 shares of our <font color="blue">common stock</font> that are reserved for     <font color="blue">issuance under</font> <font color="blue">the CEFF </font><font color="blue">arrangement</font> with Kingsbridge, 375cmam000 of which are     <font color="blue">issuable under</font> the warrant we granted to Kingsbridge</td>
    </tr>
    <tr>
      <td>The issuance of shares     of our <font color="blue">common stock</font> under <font color="blue">the CEFF </font>and upon exercise of the <font color="blue">warrant will</font>     have a <font color="blue">dilutive impact on</font> our other <font color="blue">stockholders</font> and the issuance or even     <font color="blue">potential issuance</font> of <font color="blue">such shares could</font> have a negative effect on the market     price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In addition, if we access the CEFF, we will issue     shares of our <font color="blue">common stock</font> to <font color="blue">Kingsbridge </font>at a discount of between 6prca and     10prca of the <font color="blue">daily volume weighted average price</font> of our <font color="blue">common stock</font> during a     <font color="blue">specified period</font> of <font color="blue">trading days</font> after we access the <font color="blue">CEFF Issuing </font>shares at     a <font color="blue">discount will further dilute</font> the interests of other <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>In 2005,     dlra20dtta2  million  was <font color="blue">successfully</font> raised under <font color="blue">the CEFF </font>in two separate     <font color="blue">financings</font> over 15 day periods in September and November, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>We     anticipate <font color="blue">using <font color="blue">additional</font> portions</font> of the available CEFF during 2006 to     support  <font color="blue">manufacturing</font>,  <font color="blue">development</font>  and <font color="blue">commercialization</font> <font color="blue">activities</font>     <font color="blue">associated with</font> our potential US <font color="blue">commercial launch</font> of Surfaxin late in the     <font color="blue">second quarter</font> of 2006</td>
    </tr>
    <tr>
      <td>17       _________________________________________________________________       To the extent that <font color="blue">Kingsbridge </font><font color="blue">sells shares</font> of our <font color="blue">common stock</font> <font color="blue">issued under</font>     the  CEFF  to  third  parties, our stock price may decrease due to the     <font color="blue"><font color="blue">additional</font> selling pressure</font> in the market</td>
    </tr>
    <tr>
      <td>The perceived risk of dilution     from sales of stock to or by <font color="blue">Kingsbridge </font>may cause holders of our common     stock to sell their shares, or it <font color="blue">may encourage</font> short sales of our common     stock or other similar <font color="blue">transactions</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">could contribute</font> to a decline in     the stock price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We may not be able to meet the <font color="blue">conditions</font> we are required to meet under <font color="blue">CEFF     </font>and we may not be able to access any portion of the remaining dlra47dtta6 million     <font color="blue">available under</font> <font color="blue">the CEFF </font>In addition, we are <font color="blue">dependent upon</font> the financial     ability of <font color="blue">Kingsbridge </font>to fund <font color="blue">the CEFF </font>Any <font color="blue">failure by</font> <font color="blue">Kingsbridge </font>to     perform its <font color="blue">obligations</font> under <font color="blue">the CEFF </font>could have a material adverse effect     upon us</td>
    </tr>
    <tr>
      <td>Our strategy, in many cases, is to <font color="blue">enter into</font> <font color="blue">collaboration</font> <font color="blue"><font color="blue">agreement</font>s</font> with     <font color="blue">third parties</font> <font color="blue">with respect</font> to our products and we may require <font color="blue">additional</font>     <font color="blue">collaboration</font> <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">enter into</font> these <font color="blue"><font color="blue">agreement</font>s</font> or if we     or the <font color="blue">third parties</font> do not perform under such <font color="blue"><font color="blue">agreement</font>s</font>, it <font color="blue">could impair</font>     our ability to <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>Our strategy for the <font color="blue">completion</font> of the required <font color="blue">development</font> and clinical     testing of our products and for the marketing and <font color="blue">commercialization</font> of our     products,  in  many  cases,  depends  <font color="blue">upon entering into <font color="blue">collaboration</font></font>     <font color="blue">arrangement</font>s with <font color="blue">pharmaceutical</font> companies to market, <font color="blue">commercialize</font> and     distribute our products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaboration</font> <font color="blue">arrangement</font> with Esteve for     Surfaxin and certain other of our <font color="blue">product <font color="blue">candidates</font></font> is <font color="blue">focused on key</font>     Southern  European  markets</td>
    </tr>
    <tr>
      <td>Within  these  countries, Esteve will be     responsible for the <font color="blue">development</font> and marketing of Surfaxin for a broader     portfolio of <font color="blue">indications</font>, including the prevention of RDS in premature     infants and ALI/ARDS in adults</td>
    </tr>
    <tr>
      <td>Esteve will also be responsible for the     <font color="blue">sponsorship</font>  of <font color="blue">certain clinical trial costs</font> related to obtaining EMEA     approval  for  <font color="blue">commercialization</font>  of  <font color="blue">Surfaxin  </font>in  Europe for several     <font color="blue">indications</font></td>
    </tr>
    <tr>
      <td>We will be responsible for the remainder of the <font color="blue">regulatory</font>     <font color="blue">activities</font> relating to Surfaxin, including <font color="blue">with respect</font> to EMEA filings</td>
    </tr>
    <tr>
      <td>If  we  or Esteve breach or terminate the <font color="blue"><font color="blue">agreement</font>s</font> that make up such     <font color="blue">collaboration</font>  <font color="blue">arrangement</font>s or Esteve otherwise fails to conduct their     Surfaxin-related <font color="blue">activities</font> in a <font color="blue">timely manner</font> or if there is a dispute     about their <font color="blue">obligations</font>, we may need to seek other partners or we may have     to  develop  our  own  <font color="blue">internal sales</font> and <font color="blue">marketing capability</font> for the     <font color="blue">indications</font> of Surfaxin</td>
    </tr>
    <tr>
      <td>Accordingly, we may need to <font color="blue">enter into</font> <font color="blue">additional</font>     <font color="blue">collaboration</font> <font color="blue"><font color="blue">agreement</font>s</font> and our success, particularly outside of the United     States, <font color="blue">may depend upon</font> obtaining <font color="blue">additional</font> <font color="blue">collaboration</font> partners</td>
    </tr>
    <tr>
      <td>In     addition, we <font color="blue">may depend on</font> our <font color="blue">collaborators</font>’ expertise and <font color="blue">dedication</font> of     <font color="blue">sufficient resources</font> to develop and <font color="blue">commercialize</font> our <font color="blue">proposed products</font></td>
    </tr>
    <tr>
      <td>In December, 2005, we <font color="blue">entered into</font> a <font color="blue">Strategic Alliance Agreement </font>with     <font color="blue">Chrysalis </font>to develop and <font color="blue">commercialize</font> <font color="blue">aerosolized</font> SRT to address a broad     range  of serious <font color="blue">respiratory</font> <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>Under the <font color="blue">agreement</font>, we have     exclusive rights to Chrysalis’ <font color="blue">proprietary</font> aerosolization <font color="blue">technology</font> for use     <font color="blue">with pulmonary surfactants</font> for all <font color="blue">respiratory</font> diseases and <font color="blue">conditions</font> in     hospital and <font color="blue">ambulatory settings</font></td>
    </tr>
    <tr>
      <td><font color="blue">Chrysalis </font><font color="blue">will assist with</font> the <font color="blue">development</font>     of certain combination drug-device surfactant products, and <font color="blue">provide certain</font>     <font color="blue">additional</font>  <font color="blue">consultative services</font> to us in <font color="blue"><font color="blue">connection</font> with</font> combination     drug-device surfactant products, provided that <font color="blue">certain terms</font> and <font color="blue">conditions</font>     are satisfied</td>
    </tr>
    <tr>
      <td>Additionally, <font color="blue">Chrysalis </font>is responsible for developing the     design for the aerosol device platform, patient interface and disposable     <font color="blue">dose packets</font></td>
    </tr>
    <tr>
      <td>We are responsible for <font color="blue">aerosolized</font> SRT <font color="blue">drug formulations</font>,     clinical   and   <font color="blue">regulatory</font>  <font color="blue">activities</font>,  and  the  <font color="blue">manufacturing</font>  and     <font color="blue">commercialization</font> of the drug-device products</td>
    </tr>
    <tr>
      <td>We may, in the future, grant to <font color="blue">collaboration</font> partners rights to license and     <font color="blue">commercialize</font>  <font color="blue">pharmaceutical</font>  products  developed under <font color="blue">collaboration</font>     <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>Under these <font color="blue">arrangement</font>s, our <font color="blue">collaboration</font> partners may control     <font color="blue">key <font color="blue">decisions</font></font> relating to the <font color="blue">development</font> of the products</td>
    </tr>
    <tr>
      <td>The rights of our     <font color="blue">collaboration</font>  partners  would  limit  our  <font color="blue">flexibility</font> in considering     <font color="blue">alternatives</font>  for the <font color="blue">commercialization</font> of our products</td>
    </tr>
    <tr>
      <td>If we fail to     <font color="blue">successfully</font> develop these <font color="blue">relationships</font> or if our <font color="blue">collaboration</font> partners     fail to <font color="blue">successfully</font> develop or <font color="blue">commercialize</font> any of our products, it may     delay or <font color="blue">prevent us from</font> developing or <font color="blue">commercializing</font> our products in a     <font color="blue">competitive</font> and <font color="blue">timely manner</font> and would have a material adverse effect on     the <font color="blue">commercialization</font> of Surfaxin</td>
    </tr>
    <tr>
      <td>See  Item 1A: “Risk Factors - Our limited     sales and marketing experience <font color="blue">may restrict</font> our success in <font color="blue">commercializing</font>     our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>”       18       _________________________________________________________________       If we <font color="blue">cannot protect</font> our <font color="blue">intellectual</font> property, other <font color="blue">companies could use</font>     our <font color="blue">technology</font> in <font color="blue">competitive</font> products</td>
    </tr>
    <tr>
      <td>If we infringe the <font color="blue">intellectual</font>     <font color="blue">property rights</font> of others, other companies could <font color="blue">prevent us from</font> developing     or marketing our products</td>
    </tr>
    <tr>
      <td>We <font color="blue">seek <font color="blue">patent protection</font></font> for our <font color="blue">drug <font color="blue">candidates</font></font> so as to <font color="blue">prevent others</font>     from <font color="blue">commercializing</font> equivalent products in <font color="blue"><font color="blue">substantially</font> less</font> time and at     <font color="blue"><font color="blue">substantially</font> lower expense</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">pharmaceutical</font> industry places considerable     importance  on  obtaining  patent  and <font color="blue">trade secret protection</font> for new     <font color="blue">technologies</font>, products and processes</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> in part on our     ability and that of <font color="blue">parties from whom</font> we license <font color="blue">technology</font> to:       ·     defend our patents and otherwise <font color="blue">prevent others</font> from infringing on our     <font color="blue">proprietary</font> rights;       ·     <font color="blue">protect <font color="blue">trade secrets</font></font>; and       ·     operate <font color="blue">without infringing upon</font> the <font color="blue">proprietary</font> rights of others, both in     the <font color="blue">United States </font>and in other countries</td>
    </tr>
    <tr>
      <td>The <font color="blue">patent position</font> of firms relying upon bio<font color="blue">technology</font> is <font color="blue">highly uncertain</font>     and <font color="blue">involves complex legal</font> and factual questions for <font color="blue">which important legal</font>     principles are unresolved</td>
    </tr>
    <tr>
      <td>To date, the <font color="blue">United States </font>Patent and Trademark     Office has not adopted a <font color="blue">consistent policy</font> regarding the breadth of claims     that the <font color="blue">United States </font>Patent and <font color="blue">Trademark Office </font>allows in bio<font color="blue">technology</font>     patents or the degree of protection that these types of <font color="blue">patents afford</font></td>
    </tr>
    <tr>
      <td>Even if we obtain patents to protect our products, those <font color="blue">patents may</font> not be     <font color="blue">sufficiently broad</font> and <font color="blue">others could</font> compete with us</td>
    </tr>
    <tr>
      <td>We, and the <font color="blue">parties licensing <font color="blue">technologies</font></font> to us, have <font color="blue">filed various</font> United     States and foreign patent <font color="blue">application</font>s <font color="blue">with respect</font> to the products and     <font color="blue">technologies</font>  under  our <font color="blue">development</font>, and the <font color="blue">United States </font>Patent and     <font color="blue">Trademark Office </font>and foreign <font color="blue">patent office</font>s have issued patents <font color="blue">with respect</font>     to  our  products  and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>These patent <font color="blue">application</font>s include     international <font color="blue">application</font>s filed under the <font color="blue">Patent Cooperation Treaty</font></td>
    </tr>
    <tr>
      <td>Our     pending patent <font color="blue">application</font>s, those we may file in the future or those we may     license from <font color="blue">third parties</font> may not result in the <font color="blue">United States </font>Patent and     <font color="blue">Trademark Office </font>or foreign <font color="blue">patent office</font> issuing patents</td>
    </tr>
    <tr>
      <td>Also, if patent     rights  covering our products are not <font color="blue">sufficiently broad</font>, they may not     provide us with sufficient <font color="blue">proprietary</font> protection or <font color="blue">competitive</font> advantages     <font color="blue">against <font color="blue">competitors</font> with</font> similar products and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Furthermore, if     the <font color="blue">United States </font>Patent and <font color="blue">Trademark Office </font>or foreign <font color="blue">patent office</font>s     issue patents to us or our <font color="blue">licensors</font>, others may challenge the patents or     <font color="blue">circumvent</font> the patents, or the <font color="blue">patent office</font> or the <font color="blue">courts may invalidate</font>     the patents</td>
    </tr>
    <tr>
      <td>Thus, any patents we own or license from or to <font color="blue">third parties</font>     may not provide any <font color="blue">protection against <font color="blue">competitors</font></font></td>
    </tr>
    <tr>
      <td>Furthermore, the life of our patents is limited</td>
    </tr>
    <tr>
      <td>We have licensed a series     of <font color="blue">patents from</font> Johnson &amp; Johnson and its wholly owned subsidiary, Ortho     Pharmaceutical Corporation, which are important, either individually or     <font color="blue">collectively</font>, to our strategy of <font color="blue">commercializing</font> our surfactant <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Such patents, which include relevant European patents, expire on various     <font color="blue">dates beginning</font> in 2009 and ending in 2017 or, in some cases, possibly     later</td>
    </tr>
    <tr>
      <td>We have filed, and when possible and <font color="blue">appropriate</font>, will file, other     patent <font color="blue">application</font>s <font color="blue">with respect</font> to our products and processes in the United     States and in <font color="blue">foreign countries</font></td>
    </tr>
    <tr>
      <td>We may not be able to develop <font color="blue">additional</font>     products or processes that will be patentable or <font color="blue">additional</font> <font color="blue">patents may</font> not     be  issued  to us</td>
    </tr>
    <tr>
      <td>See also Item 1A: “Risk Factors - If we <font color="blue">cannot meet</font>     <font color="blue">requirements</font> under our license <font color="blue"><font color="blue">agreement</font>s</font>, we <font color="blue">could lose</font> the rights to our     products</td>
    </tr>
    <tr>
      <td>”       <font color="blue">Intellectual </font><font color="blue">property rights</font> of <font color="blue">third parties</font> could limit our ability to     develop and market our products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">commercial success</font> also <font color="blue"><font color="blue">significant</font>ly</font> depends on our ability to operate     without  infringing the patents or violating the <font color="blue">proprietary</font> rights of     others</td>
    </tr>
    <tr>
      <td>The <font color="blue">United States </font>Patent and <font color="blue">Trademark Office </font>keeps <font color="blue">United States </font>    patent <font color="blue">application</font>s <font color="blue">confidential</font> while the <font color="blue">application</font>s are pending</td>
    </tr>
    <tr>
      <td>As a     result, we cannot determine which <font color="blue">inventions</font> <font color="blue">third parties</font> claim in pending     patent  <font color="blue">application</font>s  that  they  have filed</td>
    </tr>
    <tr>
      <td>We may need to engage in     <font color="blue">litigation</font>  to  defend  or enforce our patent and <font color="blue">license rights</font> or to     determine the scope and validity of the <font color="blue">proprietary</font> rights of others</td>
    </tr>
    <tr>
      <td>It     will be expensive and time consuming to defend and <font color="blue">enforce patent</font> claims</td>
    </tr>
    <tr>
      <td>Thus, even in those instances in which the outcome is favorable to us, the     <font color="blue">proceedings</font> can result in the diversion of substantial <font color="blue">resources from</font> our     other <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>An <font color="blue">adverse determination may</font> subject us to <font color="blue">significant</font>     <font color="blue">liabilities</font> or require us to <font color="blue">seek licenses</font> that <font color="blue">third parties</font> may not grant     to us or <font color="blue">may only grant at rates</font> that diminish or deplete the <font color="blue">profitability</font>     of the products to us</td>
    </tr>
    <tr>
      <td>An <font color="blue">adverse determination could also</font> require us to     alter our products or processes or <font color="blue">cease altogether</font> any related research and     <font color="blue">development</font> <font color="blue">activities</font> or <font color="blue">product sales</font></td>
    </tr>
    <tr>
      <td>19       _________________________________________________________________       If we <font color="blue">cannot meet</font> <font color="blue">requirements</font> under our license <font color="blue"><font color="blue">agreement</font>s</font>, we <font color="blue">could lose</font>     the rights to our products</td>
    </tr>
    <tr>
      <td>We  depend  on licensing <font color="blue"><font color="blue">agreement</font>s</font> with <font color="blue">third parties</font> to maintain the     <font color="blue">intellectual</font> <font color="blue">property rights</font> to our products under <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Presently,     we have <font color="blue">licensed rights from</font> Johnson &amp; Johnson, Ortho Pharmaceutical and     Chrysalis</td>
    </tr>
    <tr>
      <td>These  <font color="blue"><font color="blue">agreement</font>s</font>  require us to make payments and satisfy     performance  <font color="blue">obligations</font>  in  order to maintain our <font color="blue">rights under</font> these     licensing <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>All of these <font color="blue"><font color="blue">agreement</font>s</font> last either <font color="blue">throughout</font> the     life of the patents, or <font color="blue">with respect</font> to other licensed <font color="blue">technology</font>, for a     number of years after the <font color="blue">first commercial sale</font> of the <font color="blue">relevant product</font></td>
    </tr>
    <tr>
      <td>In addition, we are responsible for the cost of filing and prosecuting     certain patent <font color="blue">application</font>s and maintaining <font color="blue">certain issued patents licensed</font>     to us</td>
    </tr>
    <tr>
      <td>If we do not meet our <font color="blue">obligations</font> under our license <font color="blue"><font color="blue">agreement</font>s</font> in a     <font color="blue">timely manner</font>, we <font color="blue">could lose</font> the rights to our <font color="blue">proprietary</font> <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Finally,  we  may  be  required to obtain licenses to patents or other     <font color="blue">proprietary</font> rights of <font color="blue">third parties</font> in <font color="blue"><font color="blue">connection</font> with</font> the <font color="blue">development</font> and     use of our products and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Licenses </font>required under any such     patents  or  <font color="blue">proprietary</font>  rights  might not be made <font color="blue">available on terms</font>     acceptable to us, if at all</td>
    </tr>
    <tr>
      <td>We rely on <font color="blue">confidential</font>ity <font color="blue"><font color="blue">agreement</font>s</font> that could be breached and may be     <font color="blue">difficult</font> to enforce</td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we  believe  that  we  take  reasonable steps to protect our     <font color="blue">intellectual</font> property, including the use of <font color="blue"><font color="blue">agreement</font>s</font> relating to the     non-<font color="blue">disclosure</font> of <font color="blue">confidential</font> information to <font color="blue">third parties</font>, as well as     <font color="blue"><font color="blue">agreement</font>s</font> that purport to require the <font color="blue">disclosure</font> and <font color="blue">assignment</font> to us of     the rights to the ideas, <font color="blue">development</font>s, discoveries and <font color="blue">inventions</font> of our     employees  and <font color="blue"><font color="blue">consultants</font> while</font> we <font color="blue">employ them</font>, the <font color="blue"><font color="blue">agreement</font>s</font> can be     <font color="blue">difficult</font> and costly to enforce</td>
    </tr>
    <tr>
      <td>Although we seek to obtain these types of     <font color="blue"><font color="blue">agreement</font>s</font> from our <font color="blue">consultants</font>, advisors and <font color="blue">research <font color="blue">collaborators</font></font>, to the     extent that they apply or <font color="blue">independently</font> develop <font color="blue">intellectual</font> property in     <font color="blue">connection</font>  with  any  of  our  projects, <font color="blue">disputes may</font> arise as to the     <font color="blue">proprietary</font> rights to this type of information</td>
    </tr>
    <tr>
      <td>If a dispute arises, a court     may determine that the right belongs to a <font color="blue">third party</font>, and <font color="blue">enforcement</font> of     our rights can be costly and unpredictable</td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">will rely on</font>     <font color="blue">trade secrets</font> and <font color="blue">proprietary</font> know-how that we will seek to protect in part     by <font color="blue">confidential</font>ity <font color="blue"><font color="blue">agreement</font>s</font> with our employees, <font color="blue">consultants</font>, advisors or     others</td>
    </tr>
    <tr>
      <td>Despite the protective measures we employ, we still face the risk     that:       ·     these <font color="blue"><font color="blue">agreement</font>s</font> may be breached;       ·     these <font color="blue"><font color="blue">agreement</font>s</font> may not provide adequate remedies for the applicable type     of breach;       ·     our <font color="blue">trade secrets</font> or <font color="blue">proprietary</font> know-how will otherwise become known;       ·     our <font color="blue">competitors</font> will <font color="blue">independently</font> develop similar <font color="blue">technology</font>; or       ·     our <font color="blue">competitors</font> will <font color="blue">independently</font> discover our <font color="blue">proprietary</font> information and     <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>Our limited sales and marketing experience <font color="blue">may restrict</font> our success in     <font color="blue">commercializing</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We have limited experience in marketing or selling <font color="blue">pharmaceutical</font> products     and have a limited marketing and sales team</td>
    </tr>
    <tr>
      <td>To achieve <font color="blue">commercial success</font>     for Surfaxin, or any other <font color="blue">approved product</font>, we <font color="blue">must either rely upon</font> our     limited marketing and <font color="blue">sales force</font> and related <font color="blue">infrastructure</font>, or <font color="blue">enter into</font>     <font color="blue">arrangement</font>s with others to market and sell our products</td>
    </tr>
    <tr>
      <td>We  expect to <font color="blue">rely primarily on</font> our marketing and sales team to market     <font color="blue">Surfaxin  </font>in  the  United  States, if Surfaxin is <font color="blue">approved by</font> the FDA     Accordingly,  we  are further developing our marketing and sales team</td>
    </tr>
    <tr>
      <td><font color="blue">Developing </font>a marketing and sales team to market and sell products is a     <font color="blue">difficult</font>, <font color="blue"><font color="blue">significant</font>ly</font> expensive and time-consuming process</td>
    </tr>
    <tr>
      <td>Recruiting,     training and retaining <font color="blue">qualified sales personnel</font> is critical to our success</td>
    </tr>
    <tr>
      <td><font color="blue">Competition  </font>for <font color="blue">skilled personnel</font> is intense, and we may be unable to     attract  and  retain  a  sufficient number of qualified <font color="blue">individuals</font> to     <font color="blue">successfully</font> launch Surfaxin</td>
    </tr>
    <tr>
      <td>Additionally, we may not be able to provide     <font color="blue">adequate incentive</font> to our <font color="blue">sales force</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">successfully</font>     motivate and expand our marketing and <font color="blue">sales force</font> and further develop our     sales  and  marketing  <font color="blue">capabilities</font>,  we will have <font color="blue">difficult</font>y selling,     maintaining and increasing the sales of our products</td>
    </tr>
    <tr>
      <td>20       _________________________________________________________________       We may be unable to establish marketing, sales and <font color="blue">distribution</font> <font color="blue">capabilities</font>     <font color="blue">necessary</font> to <font color="blue">commercialize</font> and <font color="blue">gain market acceptance</font> for Surfaxin or our     other  product  <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td><font color="blue">Establishing  </font>the  expertise <font color="blue">necessary</font> to     <font color="blue">successfully</font> market and sell Surfaxin, or any other product, will require a     substantial <font color="blue">capital <font color="blue">investment</font></font></td>
    </tr>
    <tr>
      <td>We expect to incur <font color="blue">significant</font> expenses in     developing our marketing and sales team</td>
    </tr>
    <tr>
      <td>Our ability to make that <font color="blue">investment</font>     and  also  execute our current operating plan is <font color="blue">dependent on numerous</font>     factors, including, the performance of <font color="blue">third party</font> <font color="blue">collaborators</font> with whom     we  may  contract</td>
    </tr>
    <tr>
      <td>Accordingly,  we  may not have <font color="blue">sufficient funds</font> to     <font color="blue">successfully</font> <font color="blue">commercialize</font> Surfaxin or any other <font color="blue">potential product</font> in the     <font color="blue">United States </font>or elsewhere</td>
    </tr>
    <tr>
      <td>We may <font color="blue">enter into</font> <font color="blue">distribution</font> <font color="blue">arrangement</font>s and marketing alliances, which     could require us to <font color="blue">give up rights</font> to our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We may rely on third-party <font color="blue">distributors</font> to distribute our products or enter     <font color="blue">into marketing alliances</font> to sell our products</td>
    </tr>
    <tr>
      <td>We may not be successful in     entering into <font color="blue">distribution</font> <font color="blue">arrangement</font>s and <font color="blue">marketing alliances with third</font>     parties</td>
    </tr>
    <tr>
      <td>Our failure to <font color="blue">successfully</font> develop a marketing and sales team or     to <font color="blue">enter into</font> these <font color="blue">arrangement</font>s on favorable <font color="blue">terms could delay</font> or impair     our ability to <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font> and <font color="blue">could increase</font> our     costs of <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>Our dependence on <font color="blue">distribution</font> <font color="blue">arrangement</font>s and     marketing alliances to <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font> will subject us     to a number of risks, including:       ·     we may be required to <font color="blue">relinquish important rights</font> to our products or product     <font color="blue">candidates</font>;       ·     we may not be able to control the amount and timing of resources that our     <font color="blue">distributors</font> or <font color="blue">collaborators</font> may devote to the <font color="blue">commercialization</font> of our     <font color="blue">product <font color="blue">candidates</font></font>;       ·     our <font color="blue">distributors</font> or <font color="blue">collaborators</font> may experience financial <font color="blue">difficult</font>ies;       ·     our <font color="blue">distributors</font> or <font color="blue">collaborators</font> may not <font color="blue">devote sufficient</font> time to the     marketing and sales of our <font color="blue">products thereby exposing us</font> to potential     expenses in terminating such <font color="blue">distribution</font> <font color="blue"><font color="blue">agreement</font>s</font>; and       ·     business <font color="blue">combinations</font> or <font color="blue">significant</font> changes in a collaborator’s business     strategy may <font color="blue">adversely</font> affect a collaborator’s willingness or ability to     complete its <font color="blue">obligations</font> under any <font color="blue">arrangement</font></td>
    </tr>
    <tr>
      <td>We may need to <font color="blue">enter into</font> <font color="blue">additional</font> co-promotion <font color="blue">arrangement</font>s with third     parties where our own <font color="blue">sales force</font> is <font color="blue">neither well situated nor</font> large enough     to achieve <font color="blue">maximum penetration</font> in the market</td>
    </tr>
    <tr>
      <td>We may not be successful in     entering  into  any  co-promotion  <font color="blue">arrangement</font>s,  and the terms of any     co-promotion <font color="blue">arrangement</font>s may not be favorable to us</td>
    </tr>
    <tr>
      <td>In addition, if we     <font color="blue">enter into</font> co-promotion <font color="blue">arrangement</font>s or market and sell <font color="blue">additional</font> products     directly, we may need to <font color="blue">further expand</font> our <font color="blue">sales force</font> and incur <font color="blue">additional</font>     costs</td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">enter into</font> <font color="blue">arrangement</font>s with <font color="blue">third parties</font> in a <font color="blue">timely manner</font>     or if they fail to perform, it could <font color="blue">adversely</font> affect sales of our products</td>
    </tr>
    <tr>
      <td>We and any of our third-party <font color="blue">collaborators</font> must also market our products in     <font color="blue">compliance with</font> federal, state and <font color="blue">local laws</font> relating to the providing of     <font color="blue">incentives</font>  and  <font color="blue">inducements</font></td>
    </tr>
    <tr>
      <td><font color="blue">Violation  </font>of  these laws can result in     substantial penalties</td>
    </tr>
    <tr>
      <td>We have announced our intention to market and sell Surfaxin outside of the     United  States  <font color="blue">through one</font> or more <font color="blue">marketing partners upon receipt</font> of     <font color="blue"><font color="blue">regulatory</font> approval</font> abroad</td>
    </tr>
    <tr>
      <td>Although our <font color="blue">agreement</font> with Esteve provides for     <font color="blue">collaborative efforts</font> in directing a global <font color="blue">commercialization</font> effort, we     have somewhat limited <font color="blue">influence over</font> the <font color="blue">decisions</font> made by Esteve or their     <font color="blue">sublicensees</font> or the resources they devote to the marketing and <font color="blue">distribution</font>     of  Surfaxin products in their <font color="blue">licensed territory</font>, and Esteve or their     <font color="blue">sublicensees</font> may not meet their <font color="blue">obligations</font> in this regard</td>
    </tr>
    <tr>
      <td>Our marketing     and <font color="blue">distribution</font> <font color="blue">arrangement</font> with Esteve may not be successful, and we may     not receive any <font color="blue">revenues from</font> it</td>
    </tr>
    <tr>
      <td>Also, we may not be able to <font color="blue">enter into</font>     marketing and sales <font color="blue"><font color="blue">agreement</font>s</font> on acceptable terms, if at all, for <font color="blue">Surfaxin  </font>   in <font color="blue">territories</font> not covered by <font color="blue">the Esteve </font><font color="blue">agreement</font>, or for any of our other     <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>21       _________________________________________________________________       We <font color="blue">depend upon <font color="blue">key employees</font></font> and <font color="blue">consultants</font> in a <font color="blue">competitive</font> market for     <font color="blue">skilled personnel</font></td>
    </tr>
    <tr>
      <td>If we are unable to attract and retain <font color="blue">key personnel</font>, it     could <font color="blue">adversely</font> affect our ability to develop and market our products</td>
    </tr>
    <tr>
      <td>We are highly <font color="blue">dependent upon</font> the <font color="blue">principal members</font> of our <font color="blue">management team</font>,     <font color="blue">especially</font> our Chief Executive Officer, Dr</td>
    </tr>
    <tr>
      <td>Capetola, and our <font color="blue">directors</font>, as     well as our scientific advisory board members, <font color="blue">consultants</font> and <font color="blue">collaborating</font>     <font color="blue">scientists</font></td>
    </tr>
    <tr>
      <td>A loss of any of these <font color="blue">personnel may</font> have a material adverse effect on     aspects of our business and clinical <font color="blue">development</font> and <font color="blue">regulatory</font> programs</td>
    </tr>
    <tr>
      <td>As     of  March  14, 2006, we have employment <font color="blue"><font color="blue">agreement</font>s</font> with eight officers     expiring in <font color="blue">December </font>2006</td>
    </tr>
    <tr>
      <td>Each employment <font color="blue">agreement</font> provides that its term     <font color="blue">shall automatically</font> be extended for one <font color="blue">additional</font> year, unless at least 90     <font color="blue">days prior</font> to January 1 either party gives notice that it does not wish to     extend the <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>Although these employment <font color="blue"><font color="blue">agreement</font>s</font> <font color="blue">generally</font> include     non-<font color="blue">competition</font>  covenants and provide for <font color="blue">severance payments</font> that are     <font color="blue">contingent upon</font> the applicable employee’s refraining from <font color="blue">competition</font> with     us, the <font color="blue">applicable noncompete provisions</font> can be <font color="blue">difficult</font> and costly to     monitor  and enforce</td>
    </tr>
    <tr>
      <td>The loss of any of these persons’ services would     <font color="blue">adversely</font> affect our ability to develop and market our products and obtain     <font color="blue">necessary</font> <font color="blue"><font color="blue">regulatory</font> approval</font>s</td>
    </tr>
    <tr>
      <td>Further, we do not maintain key-man life     insurance</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success also will depend</font> in part on the <font color="blue">continued service</font> of our     <font color="blue">key scientific</font> and <font color="blue">management personnel</font> and our ability to identify, hire     and retain <font color="blue">additional</font> personnel, including marketing and <font color="blue">sales staff</font></td>
    </tr>
    <tr>
      <td>We     experience <font color="blue">intense <font color="blue">competition</font></font> for <font color="blue">qualified personnel</font>, and the existence of     non-<font color="blue">competition</font> <font color="blue"><font color="blue">agreement</font>s</font> between prospective employees and their former     employers may <font color="blue">prevent us from</font> hiring those <font color="blue">individuals</font> or subject us to suit     from their <font color="blue">former employers</font></td>
    </tr>
    <tr>
      <td>While we attempt to provide <font color="blue">competitive</font> compensation packages to attract and     retain <font color="blue">key personnel</font>, some of our <font color="blue">competitors</font> are likely to have greater     resources and more experience than we have, making it <font color="blue">difficult</font> for us to     compete <font color="blue">successfully</font> for <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>Our industry is highly <font color="blue">competitive</font> and we have <font color="blue">less capital</font> and resources     than many of our <font color="blue">competitors</font>, which may give them an advantage in developing     and <font color="blue">marketing products</font> similar to ours or make our <font color="blue">products obsolete</font></td>
    </tr>
    <tr>
      <td>Our  industry is highly <font color="blue">competitive</font> and subject to <font color="blue">rapid <font color="blue">technological</font></font>     innovation  and  <font color="blue">evolving industry standards</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">compete with numerous</font>     <font color="blue">existing companies intensely</font> in many ways</td>
    </tr>
    <tr>
      <td>We intend to market our products     under <font color="blue">development</font> for the treatment of diseases for which other <font color="blue">technologies</font>     and <font color="blue">treatments</font> are rapidly developing and, <font color="blue">consequently</font>, we expect new     companies to enter our industry and that <font color="blue">competition</font> in the <font color="blue">industry will</font>     increase</td>
    </tr>
    <tr>
      <td>Many of these companies have <font color="blue">substantially</font> greater research and     <font color="blue">development</font>, <font color="blue">manufacturing</font>, marketing, financial, <font color="blue">technological</font>, personnel     and  managerial  resources  than  we  have</td>
    </tr>
    <tr>
      <td>In addition, many of these     <font color="blue">competitors</font>,  either  alone or with their <font color="blue">collaborative partners</font>, have     <font color="blue"><font color="blue">significant</font>ly</font> greater experience than we do in:       ·     developing products;       ·     undertaking <font color="blue">pre<font color="blue">clinical testing</font></font> and human <font color="blue">clinical trials</font>;       ·     obtaining FDA and other <font color="blue"><font color="blue">regulatory</font> approval</font>s or products; and       ·     <font color="blue">manufacturing</font> and <font color="blue">marketing products</font></td>
    </tr>
    <tr>
      <td>Accordingly, our <font color="blue">competitors</font> may succeed in obtaining <font color="blue">patent protection</font>,     receiving FDA or comparable foreign approval or <font color="blue">commercializing</font> products     before us</td>
    </tr>
    <tr>
      <td>If we commence commercial <font color="blue">product sales</font>, we <font color="blue">will compete against</font>     <font color="blue">companies with greater marketing</font> and <font color="blue">manufacturing</font> <font color="blue">capabilities</font> who may     <font color="blue">successfully</font> develop and <font color="blue">commercialize</font> products that are more <font color="blue">effective</font> or     <font color="blue">less expensive than ours</font></td>
    </tr>
    <tr>
      <td>These are areas in which, as yet, we have limited     or no experience</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">development</font>s by our <font color="blue">competitors</font> may render     our <font color="blue">product <font color="blue">candidates</font></font> obsolete or non<font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>Presently, <font color="blue">four products</font> are <font color="blue"><font color="blue">specifically</font> approved</font> for the prevention of RDS     in <font color="blue">premature infants</font></td>
    </tr>
    <tr>
      <td>There are <font color="blue">no approved drugs</font> that are <font color="blue">specifically</font>     indicated for the prevention and treatment of ALI/ARDS in adults and current     therapy consists of general supportive care and mechanical <font color="blue">ventilation</font></td>
    </tr>
    <tr>
      <td>”       22       _________________________________________________________________       We  also  face,  and <font color="blue">will continue</font> to face, <font color="blue">competition</font> from colleges,     universities, governmental agencies and other public and <font color="blue">private research</font>     <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">competitors</font> are becoming more active in <font color="blue">seeking patent</font>     protection  and licensing <font color="blue">arrangement</font>s to <font color="blue">collect royalties</font> for use of     <font color="blue">technology</font> that they have developed</td>
    </tr>
    <tr>
      <td>Some of these <font color="blue">technologies</font> may compete     directly with the <font color="blue">technologies</font> that we are developing</td>
    </tr>
    <tr>
      <td>These institutions     will  also  compete  with us in <font color="blue">recruiting highly qualified scientific</font>     personnel</td>
    </tr>
    <tr>
      <td>We expect that therapeutic <font color="blue">development</font>s in the areas in which we     are <font color="blue">active may</font> occur at a rapid rate and that <font color="blue">competition</font> will intensify as     advances in this field are made</td>
    </tr>
    <tr>
      <td>As a result, we need to continue to devote     substantial resources and efforts to research and <font color="blue">development</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>If  we  acquire companies, products or <font color="blue">technologies</font>, we <font color="blue">may face risks</font>     <font color="blue">associated with</font> those <font color="blue">acquisition</font>s</td>
    </tr>
    <tr>
      <td>If we are presented with <font color="blue">appropriate</font> opportunities, we intend to acquire or     make other <font color="blue">investment</font>s in complementary companies, products or <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We may not realize the anticipated benefit of any <font color="blue">acquisition</font> or <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>If  we  acquire  companies or <font color="blue">technologies</font>, we <font color="blue">will likely</font> face risks,     <font color="blue">uncertainties</font> and disruptions <font color="blue">associated with</font> the <font color="blue">integration</font> process,     including <font color="blue">difficult</font>ies in the <font color="blue">integration</font> of these <font color="blue">operations</font> and services     of  an  acquired  company, <font color="blue">integration</font> of acquired <font color="blue">technology</font> with our     products,  diversion of our management’s attention from other business     concerns, the <font color="blue">potential loss</font> of <font color="blue">key employees</font> or customers of the acquired     <font color="blue">businesses</font>  and  <font color="blue">impairment</font>  charges if future <font color="blue">acquisition</font>s are not as     <font color="blue">successful as</font> we <font color="blue">originally</font> anticipate</td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">successfully</font> integrate     other companies, products or <font color="blue">technologies</font> that we may acquire, our business     could be harmed</td>
    </tr>
    <tr>
      <td>Furthermore, we may have to incur debt or <font color="blue">issue equity</font>     securities to pay for any <font color="blue">additional</font> future <font color="blue">acquisition</font>s or <font color="blue">investment</font>s, the     issuance  of  <font color="blue">which could</font> be dilutive to our <font color="blue">existing shareholders</font></td>
    </tr>
    <tr>
      <td>In     addition, our operating results may suffer because of <font color="blue">acquisition</font>-related     costs or <font color="blue">amortization expenses</font> or charges relating to acquired intangible     assets</td>
    </tr>
    <tr>
      <td>If <font color="blue">product <font color="blue">liability</font></font> claims are <font color="blue">brought against us</font>, it may result in reduced     demand for our products or damages that exceed our <font color="blue">insurance coverage</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">clinical testing</font> of, marketing and use of our products exposes us to     product  <font color="blue">liability</font> claims in the event that the use or misuse of those     products causes injury, disease or results in <font color="blue">adverse effects</font></td>
    </tr>
    <tr>
      <td>Use of our     products in <font color="blue">clinical trials</font>, as well as commercial sale, could result in     <font color="blue">product <font color="blue">liability</font></font> claims</td>
    </tr>
    <tr>
      <td>In addition, sales of our <font color="blue">products through third</font>     party <font color="blue">arrangement</font>s could also subject us to <font color="blue">product <font color="blue">liability</font></font> claims</td>
    </tr>
    <tr>
      <td>We     presently carry <font color="blue">product <font color="blue">liability</font></font> insurance with coverages of up to dlra10     million  <font color="blue">per occurrence</font> and dlra10 million in the aggregate, an amount we     consider  reasonable  and customary relating to our <font color="blue">clinical trials</font> of     Surfaxin</td>
    </tr>
    <tr>
      <td>However, this <font color="blue">insurance coverage</font> includes <font color="blue">various deductibles</font>,     <font color="blue">limitations</font> and <font color="blue">exclusions from coverage</font>, and in any <font color="blue">event might</font> not fully     cover  any  potential claims</td>
    </tr>
    <tr>
      <td>We may need to obtain <font color="blue">additional</font> product     <font color="blue">liability</font> <font color="blue">insurance coverage</font> prior to initiating other <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>We     expect   to   obtain   product  <font color="blue">liability</font>  insurance  coverage  before     <font color="blue">commercialization</font>  of our <font color="blue">proposed products</font>; however, the insurance is     expensive and <font color="blue">insurance companies may</font> not issue this type of insurance when     we need it</td>
    </tr>
    <tr>
      <td>We may not be able to obtain <font color="blue">adequate insurance</font> in the future at     an acceptable cost</td>
    </tr>
    <tr>
      <td>Any <font color="blue">product <font color="blue">liability</font></font> claim, even one that was not in     excess  of  our  insurance  coverage  or  one that is meritless and/or     <font color="blue">unsuccessful</font>, could <font color="blue">adversely</font> affect our <font color="blue">cash available</font> for other purposes,     <font color="blue">such as research</font> and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>In addition, the existence of a product     <font color="blue">liability</font> claim <font color="blue">could affect</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We expect to <font color="blue">face uncertainty over reimbursement</font> and <font color="blue">healthcare reform</font></td>
    </tr>
    <tr>
      <td>In both the <font color="blue">United States </font>and other countries, sales of our <font color="blue">products will</font>     depend in part upon the <font color="blue">availability</font> of reimbursement from <font color="blue">third party</font>     payors, which include government health administration <font color="blue">authorities</font>, managed     care  providers  and  private  <font color="blue">health insurers</font></td>
    </tr>
    <tr>
      <td>Third <font color="blue">party payors</font> are     <font color="blue">increasingly challenging</font> the price and examining the cost <font color="blue">effective</font>ness of     <font color="blue">medical products</font> and services</td>
    </tr>
    <tr>
      <td>Directors,  executive  officers, principal <font color="blue">stockholders</font> and <font color="blue">affiliated</font>     entities own a <font color="blue">significant</font> percentage of our <font color="blue">capital stock</font>, and they may     make <font color="blue">decisions</font> that you do not consider to be in your <font color="blue">best interest</font></td>
    </tr>
    <tr>
      <td>As  of <font color="blue">December </font>31, 2005, our <font color="blue">directors</font>, executive officers, principal     <font color="blue">stockholders</font> and <font color="blue">affiliated</font> entities <font color="blue">beneficial</font>ly owned, in the aggregate,     approximately 16prca of our <font color="blue">outstanding voting securities</font></td>
    </tr>
    <tr>
      <td>As a result, if some     or  all  of  them acted together, they would have the ability to exert     substantial <font color="blue">influence over</font> the election of our <font color="blue">Board of <font color="blue">Directors </font></font>and the     outcome of issues requiring <font color="blue">approval by</font> our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">concentration</font>     of <font color="blue">ownership may</font> have the effect of delaying or preventing a change in     control of our company that may be <font color="blue">favored by</font> other <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>This could     prevent <font color="blue">transactions</font> in which <font color="blue">stockholders</font> might otherwise recover a premium     for their shares over current <font color="blue">market price</font>s</td>
    </tr>
    <tr>
      <td>23       _________________________________________________________________       The  market  price  of  our  stock may be <font color="blue">adversely</font> affected by market     <font color="blue">volatility</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font>, like that of many other <font color="blue">development</font>     stage <font color="blue">pharmaceutical</font> or bio<font color="blue">technology</font> companies, has been and is likely to     be  volatile</td>
    </tr>
    <tr>
      <td>In  addition  to general economic, political and market     <font color="blue">conditions</font>, the price and <font color="blue">trading volume</font> of our <font color="blue">stock could fluctuate widely</font>     in response to many factors, including:       ·     <font color="blue">announcements</font> of the results of <font color="blue">clinical trials</font> by us or our <font color="blue">competitors</font>;       ·     <font color="blue">adverse reactions</font> to products;       ·     <font color="blue">governmental approvals</font>, delays in expected <font color="blue">governmental approvals</font> or     <font color="blue">withdrawals</font> of any prior <font color="blue">governmental approvals</font> or public or <font color="blue">regulatory</font>     <font color="blue">agency concerns</font> regarding the safety or <font color="blue">effective</font>ness of our products;       ·     changes in the <font color="blue">United States </font>or foreign <font color="blue">regulatory</font> policy during the period     of product <font color="blue">development</font>;       ·     <font color="blue">development</font>s in patent or other <font color="blue">proprietary</font> rights, including any third     <font color="blue">party challenges</font> of our <font color="blue">intellectual</font> <font color="blue">property rights</font>;       ·     <font color="blue">announcements</font> of <font color="blue">technological</font> innovations by us or our <font color="blue">competitors</font>;       ·     <font color="blue">announcements</font> of <font color="blue">new products</font> or <font color="blue">new contracts by us</font> or our <font color="blue">competitors</font>;       ·     actual or anticipated <font color="blue">variations</font> in our operating results due to the level     of <font color="blue">development</font> expenses and other factors;       ·     changes in financial estimates <font color="blue">by securities analysts</font> and whether our     <font color="blue">earnings meet</font> or exceed the estimates;       ·     <font color="blue">conditions</font> and trends in the <font color="blue">pharmaceutical</font> and other <font color="blue">industries</font>;       ·     <font color="blue">new accounting standards</font>; and       ·     the occurrence of any of the <font color="blue">risks described</font> in this Item 1A       Our <font color="blue">common stock</font> is listed for <font color="blue">quotation on</font> <font color="blue">The NASDAQ <font color="blue">National Market</font></font></td>
    </tr>
    <tr>
      <td>During the twelve month period ended <font color="blue">December </font>31, 2005, the price of our     <font color="blue">common stock</font> has ranged from dlra5dtta05 to dlra9dtta15</td>
    </tr>
    <tr>
      <td>We expect the price of our     <font color="blue">common stock</font> to <font color="blue">remain volatile</font></td>
    </tr>
    <tr>
      <td>The average daily <font color="blue">trading volume</font> in our     common  stock  varies <font color="blue"><font color="blue">significant</font>ly</font></td>
    </tr>
    <tr>
      <td>For the twelve month period ended     <font color="blue">December </font>31, 2005, the average daily <font color="blue">trading volume</font> in our <font color="blue">common stock</font> was     approximately 560cmam000 shares and the average number of <font color="blue">transactions</font> per day     was approximately 1cmam795</td>
    </tr>
    <tr>
      <td>Our <font color="blue">relatively low average volume</font> and low average     number of <font color="blue">transactions</font> per day may affect the ability of our <font color="blue">stockholders</font> to     sell their shares in the <font color="blue">public market at prevailing prices</font> and a more     <font color="blue">active market may never</font> develop</td>
    </tr>
    <tr>
      <td>In addition, we may not be able to continue to adhere to the <font color="blue">strict listing</font>     criteria of the <font color="blue">National Market</font></td>
    </tr>
    <tr>
      <td>If the <font color="blue">common stock</font> were no longer listed     on the <font color="blue">National Market</font>, investors might only be able to trade on the Nasdaq     Capital Market, in the over-the-counter market in the Pink Sheets^® (a     quotation medium operated by the National Quotation Bureau, LLC) or on the     OTC Bulletin Board^® of the National Association of Securities Dealers, Inc</td>
    </tr>
    <tr>
      <td>This <font color="blue">would impair</font> the liquidity of our securities not only in the number of     shares  that could be bought and sold at a given price, which might be     <font color="blue">depressed by</font> the relative illiquidity, but also through delays in the timing     of <font color="blue">transactions</font> and reduction in <font color="blue">media coverage</font></td>
    </tr>
    <tr>
      <td>In the past, following periods of <font color="blue">volatility</font> in the <font color="blue">market price</font> of the     securities of companies in our industry, securities class action <font color="blue">litigation</font>     has <font color="blue">often been instituted against companies</font> in our industry</td>
    </tr>
    <tr>
      <td>If we face     securities <font color="blue">litigation</font> in the future, even if meritless or <font color="blue">unsuccessful</font>, it     would result in substantial costs and a diversion of <font color="blue">management attention</font>     and resources, <font color="blue">which would</font> negatively impact our business</td>
    </tr>
    <tr>
      <td>A substantial number of our securities are eligible for future sale and this     could  affect  the <font color="blue">market price</font> for our stock and our ability to raise     capital</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> could drop due to sales of a large     number of shares of our <font color="blue">common stock</font> or the <font color="blue">perception</font> that these sales     could occur</td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, we had 61cmam021cmam694 shares of common     <font color="blue">stock issued</font> and outstanding</td>
    </tr>
    <tr>
      <td>24       _________________________________________________________________       We have a <font color="blue">universal shelf <font color="blue">registration statement</font> on</font> Form S-3 (File Nodtta     333-128929),  <font color="blue">filed with</font> the SEC on October 11, 2005, for the proposed     offering from time to time of up to dlra100 million of our debt or equity     securities, of which dlra80 million is remaining</td>
    </tr>
    <tr>
      <td>We have no immediate plans to     sell any <font color="blue">securities under</font> this <font color="blue">registration statement</font></td>
    </tr>
    <tr>
      <td>However, we may issue     <font color="blue">securities from</font> time to time in response to market <font color="blue">conditions</font> or other     <font color="blue">circumstances on terms</font> and <font color="blue">conditions</font> that will be determined at such time</td>
    </tr>
    <tr>
      <td>Additionally, there are 10cmam587cmam651 shares of our <font color="blue">common stock</font> that are     <font color="blue">currently reserved</font> for <font color="blue">issuance under</font> <font color="blue">the CEFF </font>See Item 1A: “Risk Factors -     <font color="blue">Our Committed Equity Financing Facility </font>may have a <font color="blue">dilutive impact on</font> our     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>”       <font color="blue">As of <font color="blue">December </font></font>31, 2005, up to 10cmam903cmam542 shares of our <font color="blue">common stock</font> were     <font color="blue">issuable upon exercise</font> of <font color="blue">outstanding options</font> and warrants</td>
    </tr>
    <tr>
      <td>Holders of our     stock options and warrants are likely to exercise them, if ever, at a time     when we otherwise could obtain a price for the sale of our securities that     is <font color="blue">higher than</font> the <font color="blue">exercise price per security</font> of the options or warrants</td>
    </tr>
    <tr>
      <td>This exercise, or the <font color="blue">possibility</font> of this exercise, may impede our efforts     to obtain <font color="blue"><font color="blue">additional</font> financing</font> through the sale of <font color="blue">additional</font> securities or     make this financing more costly, and may reduce the price of our common     stock</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Provisions </font> </font>of  our  Certificate of Incorporation, Shareholders Rights     Agreement and Delaware <font color="blue">law could defer</font> a change of our <font color="blue">management which</font>     <font color="blue">could discourage</font> or <font color="blue">delay offers</font> to acquire us</td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>of our Restated Certificate of Incorporation, as amended, our     <font color="blue">Shareholders Rights Agreement and Delaware </font>law may make it more <font color="blue">difficult</font>     for someone to acquire control of us or for our <font color="blue">stockholders</font> to remove     <font color="blue">existing management</font>, and <font color="blue">might discourage</font> a <font color="blue">third party</font> from offering to     acquire us, even if a change in control or in <font color="blue">management would</font> be <font color="blue">beneficial</font>     to our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>For example, our Restated Certificate of Incorporation,     as amended, allows us to <font color="blue">issue shares</font> of <font color="blue"><font color="blue">preferred stock</font> without</font> any vote or     <font color="blue">further action by</font> our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">Board of <font color="blue">Directors </font></font>has the authority     to fix and determine the <font color="blue">relative rights</font> and <font color="blue">preferences</font> of <font color="blue">preferred stock</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">Board of <font color="blue">Directors </font></font>also has the authority to issue <font color="blue">preferred stock</font>     <font color="blue">without further stockholder approval</font></td>
    </tr>
    <tr>
      <td>As a result, our Board of <font color="blue"><font color="blue">Directors </font> </font>   <font color="blue">could authorize</font> the issuance of a series of <font color="blue">preferred stock</font> that <font color="blue">would grant</font>     to holders the preferred right to our <font color="blue">assets upon liquidation</font>, the right to     receive <font color="blue">dividend payments</font> before dividends are <font color="blue">distributed</font> to the holders of     <font color="blue">common stock</font> and the right to the <font color="blue">redemption</font> of the shares, together with a     premium, prior to the <font color="blue">redemption</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In addition, our Board     of Directors, <font color="blue">without further stockholder approval</font>, could issue large blocks     of <font color="blue">preferred stock</font></td>
    </tr>
    <tr>
      <td>We have adopted a shareholders rights <font color="blue">agreement</font> which     under certain circumstances would <font color="blue"><font color="blue">significant</font>ly</font> impair the ability of third     parties to acquire control of <font color="blue">us without prior approval</font> of our Board of     <font color="blue">Directors </font>thereby discouraging unsolicited takeover proposals</td>
    </tr>
    <tr>
      <td>The rights     <font color="blue">issued under</font> the shareholders rights <font color="blue">agreement</font> would cause substantial     dilution to a person or group that attempts to acquire us on terms not     approved in <font color="blue">advance by</font> our <font color="blue">Board of Directors</font></td>
    </tr>
  </tbody>
</table>